Precision Medicine

San Diego – November 04, 2026 -- Circular Genomics and PharmatrophiX have launched a biomarker collaboration that applies blood-based circular RNA (circRNA) profiling to LM11A-31, PharmatrophiX's first-in-class Alzheimer's candidate, with possible extension across the company's neurodegeneration pipeline.

Planned open-label study is the first test of the circRNA platform

The initial workstream centers on PharmatrophiX's planned open-label Alzheimer's biomarker study of LM11A-31, a small molecule targeting the p75 neurotrophin receptor (p75NTR). Circular Genomics will use its research-use-only CircPath platform to characterize baseline molecular heterogeneity and track pathway-level changes during treatment.

Austin – November 04, 2026 -- Genprex, Inc. (NASDAQ: GNPX) reported that low TROP2 expression was consistently associated with primary resistance to its lead gene therapy Reqorsa (quaratusugene ozeplasmid) across multiple preclinical non-small cell lung cancer (NSCLC) models. The company says the finding could guide patient selection in future trials.

About half of tested NSCLC models showed primary resistance

Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery. Protein-expression analyses identified low TROP2 expression as a marker associated with that resistance.

Patient biopsies from a TUSC2 trial back the association

Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the link between TROP2 expression and treatment response. The company did not disclose patient numbers or effect sizes.

Singapore – November 02, 2026 -- Ultima Genomics' UG200 Sequencing Platform has been selected for the SG-INSIGHT cohort of Phase III of Singapore's National Precision Medicine (NPM) program, which will cover about 450,000 individuals. The company calls it its first major win supporting a national-scale clinical whole genome sequencing initiative. Financial terms were not disclosed.

Phase III targets nearly one in 10 Singapore residents

NPM Phase III is about 4.5 times the size of Phase II, which sequenced 100,000 Singaporeans. The new phase also shifts from healthy individuals to patients across a wide spectrum of health conditions. Participants will come from Singapore's three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth.

United States – October 27, 2026 -- Truveta aims to enroll tens of millions of consenting participants in the Truveta Genome Project. The goal is the largest and most diverse database of genotypic and phenotypic information ever assembled, according to Kristin Rand, the company's Senior Director of Genomics Partnerships.

The project has moved from planning to enrolling participants and collecting samples, roughly 15 months after Truveta announced it. It builds a consented, de-identified genomic dataset linked with longitudinal clinical data, treatments and outcomes. Truveta has not disclosed current enrollment figures or the number of participating health systems.

San Mateo – October 19, 2026 -- Helix will present three-year outcomes from CDC Tier 1 genomic screening of 527,000 participants at the opening plenary of the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20-24 in Montreal. The company says its GenoSphereTM resource now holds more than 620,000 paired EHR, claims and genomics records.

Helix Research Network supplies the plenary data from 17 health systems

The plenary study draws on the Helix Research Network (HRN), which Helix describes as the world's largest precision health network. All 17 member health systems offer CDC Tier 1 primary screening to every patient who enrolls in research. The study examines how surfacing previously undiagnosed genetic risk can improve screening and preventive care across diverse health systems.

Cassie Hajek, MD, Medical Director, will deliver the talk on Tuesday, October 20, from 5:57 to 6:15 p.m. ET in Room 517.

Sheridan – October 16, 2026 -- The global cancer diagnostics market is valued at USD 29.3 billion in 2026 and is projected to reach USD 41.5 billion by 2031, a CAGR of 7.2%, according to a new study by Wissen Research.

Demand starts with patient volume. The International Agency for Research on Cancer counted about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and expects annual new cases to pass 35 million by 2050. Each patient may need screening, diagnosis, staging, molecular characterization and follow-up.

Friendswood – October 13, 2026 -- Management recommendations changed in line with TissueCypher risk classifications for 96% of patients in a multi-center Barrett's esophagus cohort, according to data Castle Biosciences (Nasdaq: CSTL) is presenting at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Oct. 9-14.

The company is presenting three studies: two case reports and one multi-center cohort study. All three examine whether the molecular test adds risk information beyond histopathology.

TissueCypher and clinicopathologic scoring agreed only slightly in the multi-center cohort

The cohort study (P5192) compared TissueCypher with the Progression in Barrett's (PIB) clinicopathologic approach and found only slight agreement (Cohen's κ = 0.04). TissueCypher classified 83% of patients as low risk and 17% as intermediate/high risk. The PIB score classified 31% as low risk and 69% as intermediate/high risk.

Oxford, England – October 06, 2026 -- Perspectum, an Oxford-based precision health company, has appointed Warren Cresswell as Chief Executive Officer, bringing more than 25 years of diagnostics and medical device leadership to the firm's push into liver and cardiometabolic disease imaging. The placement was executed by Slone Partners, a nationwide executive search firm serving life sciences and healthcare organizations.

Cresswell previously led Nestlé-owned Prometheus Laboratories through a growth phase

Cresswell served as President and CEO of Prometheus Laboratories, a Nestlé Health Science company, where he directed the diagnostics business through a period of significant expansion. He has built commercial and CLIA-certified laboratory infrastructure supporting FDA-cleared diagnostics in the United States and most recently served as CEO of a precision oncology company.

San Carlos, Calif. – October 05, 2026 -- A non-invasive urine test can now predict whether bladder cancer patients will respond to immunotherapy before treatment even begins, according to a Stanford-led study published in Nature Medicine and announced by Resero Bio.

Study analyzed 683 urine samples to validate cell-free RNA platform

Researchers from Stanford Cancer Institute and the VA Palo Alto Health Care System used uRARE-seq, Resero Bio's proprietary targeted cfRNA sequencing method, to analyze 683 urine samples from bladder cancer patients and controls. The platform distinguished low-grade from high-grade tumors and non-muscle invasive from muscle-invasive disease, determinations that currently require tissue biopsy or surgical resection.

Pune, India – September 25, 2026 -- The global nanomedicine market reached USD 207.91 billion in 2025 and is projected to hit USD 581.2 billion by 2034, expanding at a 12.1% compound annual growth rate, according to a new report from Maximize Market Research.

North America commands the largest share on pharmaceutical R&D strength

North America held the largest share of the market in 2025, driven by advanced healthcare infrastructure, deep pharmaceutical and biotechnology research pipelines, and high healthcare expenditure. The United States anchors regional growth through its established research ecosystem and rising adoption of nanotechnology-based drug delivery, diagnostics and precision medicine platforms. Canada and Mexico are contributing through expanding healthcare capabilities and research initiatives.